Divi's Laboratories Limited (NSE:DIVISLAB)
India
· Delayed Price · Currency is INR 6,835.00
-9.50 (-0.14%)
Jul 11, 2025, 3:30 PM IST
Divi's Laboratories Revenue
In the fiscal year ending March 31, 2025, Divi's Laboratories had annual revenue of 93.60B INR with 19.31% growth. Divi's Laboratories had revenue of 25.85B in the quarter ending March 31, 2025, with 12.24% growth.
Revenue
93.60B
Revenue Growth
+19.31%
P/S Ratio
19.39
Revenue / Employee
9.61M
Employees
9,741
Market Cap
1,814.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 93.60B | 15.15B | 19.31% |
| Mar 31, 2024 | 78.45B | 780.00M | 1.00% |
| Mar 31, 2023 | 77.67B | -11.93B | -13.31% |
| Mar 31, 2022 | 89.60B | 19.90B | 28.56% |
| Mar 31, 2021 | 69.69B | 15.75B | 29.20% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Glenmark Pharmaceuticals | 134.35B |
| Fortis Healthcare | 77.83B |
Divi's Laboratories News
- 6 weeks ago - Morgan Stanley maintains overweight on Divis Labs, sees 11% upside after second global order win - Business Upturn
- 7 weeks ago - Divis Laboratories signs long-term supply deal with global pharma company - Business Upturn
- 7 weeks ago - BHEL, Hyundai & more: Top stocks on brokers' radar today - The Times of India
- 7 weeks ago - Stocks in news today: Divis Labs, Delhivery, Premier Energies, Zen Tech, KRBL, Galaxy Surfactants, Kaynes Tech after Q4 earnings on May 19 - Business Upturn
- 5 months ago - Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 5 months ago - Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi - Business Upturn
- 7 months ago - Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays - Business Upturn